Northern Trust Corp Grows Stake in Moderna, Inc. (NASDAQ:MRNA)

Northern Trust Corp increased its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 13.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,959,054 shares of the company's stock after acquiring an additional 354,871 shares during the period. Northern Trust Corp owned about 0.77% of Moderna worth $123,037,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC grew its position in Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after buying an additional 1,282,469 shares during the period. Geode Capital Management LLC increased its position in Moderna by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after buying an additional 171,774 shares during the last quarter. Invesco Ltd. raised its stake in shares of Moderna by 24.3% in the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock valued at $208,169,000 after buying an additional 979,858 shares during the period. Norges Bank bought a new position in shares of Moderna during the 4th quarter worth $163,833,000. Finally, The Manufacturers Life Insurance Company raised its stake in Moderna by 8.7% in the 4th quarter. The Manufacturers Life Insurance Company now owns 3,341,924 shares of the company's stock valued at $138,957,000 after acquiring an additional 267,990 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Stock Down 1.6 %

Moderna stock traded down $0.40 during trading hours on Wednesday, hitting $24.04. The stock had a trading volume of 7,625,730 shares, compared to its average volume of 7,504,427. The stock's 50-day moving average price is $29.27 and its 200-day moving average price is $37.07. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $170.47. The stock has a market capitalization of $9.29 billion, a P/E ratio of -2.59 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The business had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The business's quarterly revenue was down 35.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.07) EPS. On average, research analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on MRNA shares. The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Leerink Partners cut their target price on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Barclays decreased their price target on Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Friday, May 2nd. Evercore ISI cut their price objective on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Finally, UBS Group decreased their target price on shares of Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Moderna has a consensus rating of "Hold" and a consensus price target of $53.95.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.